SCHEMBL7550865

SCHEMBL7550865

CC(C)(CC1CCNCC1)NC(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA5 P31644 3/20 0.39
GABRB2 P47870 3/20 0.39
SLC6A1 P30531 2/20 0.39
SLC6A12 P48065 2/20 0.39
SLC6A11 P48066 2/20 0.39
SLC6A13 Q9NSD5 2/20 0.39
GABRA1 P14867 2/20 0.39
GABRA4 P48169 2/20 0.39
GABRR1 P24046 1/20 0.39
ALOX15 P16050 2/20 0.38
CPN1 P15169 2/20 0.38
CPB2 Q96IY4 2/20 0.38
TSHR P16473 2/20 0.36
GABRP O00591 1/20 0.36
GABRD O14764 1/20 0.36
GABRB1 P18505 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA3 P34903 1/20 0.36
GABRA2 P47869 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28187856 0.91 SLC6A1 (0.50) GABRA5GABRB2SLC6A1SLC6A12SLC6A11
SCHEMBL28469067 0.91 SLC6A1 (0.50) GABRA5GABRB2SLC6A1SLC6A12SLC6A11
SCHEMBL28529272 0.84 THRA (0.36) EPHX1
SCHEMBL3683641 0.84 THRA (0.36) EPHX1
SCHEMBL29172797 0.83 ITGB3 (0.42) GABRA5GABRB2SLC6A1SLC6A12SLC6A11
SCHEMBL27528169 0.83 ALOX15 (0.36) GABRA5GABRB2SLC6A1SLC6A12SLC6A11
SCHEMBL28647404 0.82
SCHEMBL29172713 0.81 ITGB3 (0.41) GABRA5GABRB2SLC6A1SLC6A12SLC6A11
SCHEMBL28547274 0.81 CPN1 (0.44) GABRA5GABRB2SLC6A1SLC6A12SLC6A11
SCHEMBL28482355 0.81 CPN1 (0.44) GABRA5GABRB2SLC6A1SLC6A12SLC6A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159491-A1 Antimicrobial Compounds and Methods NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-25 US disclosed
EP-3911644-A1 ANTIMICROBIAL COMPOUNDS AND METHODS Curza Global LLC (US) 2021-11-24 EP disclosed
WO-2020150385-A1 ANTIMICROBIAL COMPOUNDS AND METHODS CURZA GLOBAL, LLC (US) 2020-07-23 WO disclosed
US-20020052513-A1 Oxamide IMPDH inhibitors HOFFMANN-LA ROCHE INC. 2002-05-02 US disclosed
EP-1127883-A2 Oxamides as IMPDH inhibitors F. HOFFMANN-LA ROCHE AG (CH) 2001-08-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159491-A1 Antimicrobial Compounds and Methods MPO, NISCH, RPN2 GABRA5 3875/4885GABRB2 3992/4885SLC6A1 3404/4885
US-20020052513-A1 Oxamide IMPDH inhibitors IMPDH1, IMPDH2, IMPA1 GABRA5 3841/4885GABRB2 2668/4885SLC6A1 1470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.